Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Biosimilars ‘Bumpy’ For Teva As It Prepares For Alvotech Inspection

CEO Hints At More Deals On The Horizon Despite A Degree Of Market Uncertainty

Executive Summary

Offering the latest details on Teva’s biosimilars strategy, CEO Richard Francis spoke about how the firm is looking to bring Alvotech’s FDA filings to the finish line as well as hinting at future biosimilars partnership deals. At the same time, he acknowledged a “bumpy” US market with a degree of uncertainty that has led the firm to allocate capital accordingly.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts